ORC ID ">
  • Users Online: 596
  • Home
  • Print this page
  • Email this page
REVIEW
Year : 2022  |  Volume : 17  |  Issue : 8  |  Page : 1717-1725

Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems


1 Department of Pharmacology and Experimental Therapeutics; Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA
2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
3 Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA

Correspondence Address:
Zahoor A Shah
Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH
USA
Login to access the Email id

Source of Support: A Scholarship supported Daniyah Almarghalani from Taif University, Saudi Arabia Cultural Mission. The work was partly supported by the grants from American Heart Association #17AIREA33700076/ZAS/2017 and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health #R01NS112642 to ZAS, Conflict of Interest: None


DOI: 10.4103/1673-5374.332129

Rights and Permissions

Intracerebral hemorrhage (ICH) is a subtype of stroke associated with higher rates of mortality. Currently, no effective drug treatment is available for ICH. The molecular pathways following ICH are complicated and diverse. Nucleic acid therapeutics such as gene knockdown by small interfering RNAs (siRNAs) have been developed in recent years to modulate ICH’s destructive pathways and mitigate its outcomes. However, siRNAs delivery to the central nervous system is challenging and faces many roadblocks. Existing barriers to systemic delivery of siRNA limit the use of naked siRNA; therefore, siRNA-vectors developed to protect and deliver these therapies into the specific-target areas of the brain, or cell types seem quite promising. Efficient delivery of siRNA via nanoparticles emerged as a viable and effective alternative therapeutic tool for central nervous system-related diseases. This review discusses the obstacles to siRNA delivery, including the advantages and disadvantages of viral and nonviral vectors. Additionally, we provide a comprehensive overview of recent progress in nanotherapeutics areas, primarily focusing on the delivery system of siRNA for ICH treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed218    
    Printed2    
    Emailed0    
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal